Table 4:

Maternal and infant characteristics in cases of vertically infected infants, 2011–2016

Case no.	Maternal				Infant

	Timing of HIV diagnosis	Duration of antenatal combination antiretroviral therapy, wk	Adherence	Viral load, copies/mL	Gestational age, wk^*	Birth weight, kg	Sex	Age at first positive HIV PCR result, d	Antiretroviral prophylaxis^†
1	Preconception	≥ 4	Suboptimal	≥ 1000	37	3.28	Female	1	ZDV/3TC/NVP

2	Preconception	< 4	Suboptimal	Unknown	36	1.64	Male	1	ZDV/3TC/NVP

3	Preconception	< 4	Suboptimal	Unknown	36	2.27	Female	1	ZDV/3TC/NVP

4	Preconception	< 4	Suboptimal	< 50	38	2.65	Female	1309	ZDV/3TC

5	Second trimester	≥ 4	Suboptimal	Unknown	34	2.11	Female	2	ZDV/3 doses NVP

6	Intrapartum	NA	NA	50–999	40	2.97	Male	10	ZDV/3TC/3 doses NVP

7	Intrapartum	NA	NA	Unknown	39	2.76	Male	2	ZDV/3TC/NVP

8	Intrapartum	NA	NA	Unknown	33	1.75	Female	1	ZDV/1 dose NVP

9	Intrapartum	NA	NA	≥ 1000	35	1.75	Female	1	ZDV/3TC/NVP

10	Intrapartum	NA	NA	≥ 1000	39	2.76	Male	2	ZDV/3TC/NFV^‡

11	After delivery	NA	NA	Unknown	39	3.00	Female	129	None

12	After delivery	NA	NA	Unknown	41	Unknown	Male	122	None

13	After delivery	NA	NA	Unknown	37	3.40	Male	264	None

14	After delivery	NA	NA	Unknown	40	2.88	Female	484	None

Note: 3TC = lamivudine, NA = not applicable, NFV = nelfinavir, NVP = nevirapine, PCR = polymerase chain reaction, ZDV = zidovudine.
↵* Mode of delivery was spontaneous vaginal delivery except in cases 1, 12 and 13 (elective cesarean birth).
↵† All medications were administered at treatment dosages except where noted otherwise.
↵‡ Also received 3 doses of nevirapine during first week of life.